Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Impulsin
2. Mimyx
3. N-(2-hydroxyethyl)palmitate
4. N-palmitoylethanolamine
5. Palmidrol
6. Palmitylethanolamide
1. Palmidrol
2. 544-31-0
3. N-(2-hydroxyethyl)hexadecanamide
4. Palmitoyl Ethanolamide
5. Impulsin
6. Palmitamide Mea
7. N-palmitoylethanolamine
8. Loramine P 256
9. Hydroxyethylpalmitamide
10. Palmitic Acid Monoethanolamide
11. N-(2-hydroxyethyl)palmitamide
12. Palmitoyl-ea
13. Palmitylethanolamide
14. Palmidrolum
15. Hexadecanamide, N-(2-hydroxyethyl)-
16. Palmidrol [inn]
17. Monoethanolamine Palmitic Acid Amide
18. Levagen
19. Anandamide (16:0)
20. N-palmitoyl Ethanolamine
21. Palmitic Monoethanolamide
22. Palmdrol Prodes
23. N-hexadecanoylethanolamine
24. Palmitinsaeure-beta-hydroxyethylamid
25. Nsc 23320
26. Hexadecanoyl Ethanolamide
27. Nsc-23320
28. N-hexadecanoyl-ethanolamine
29. N(2-hydroxyethyl)palmitide
30. Am 3112
31. 6r8t1udm3v
32. N(2-hydroxyethyl) Palmitide
33. N-(2-hydroxyethyl)-palmitide
34. Chebi:71464
35. Fsd-201
36. Palmidrol (inn)
37. Ncgc00015793-03
38. Am 3112;loramine P 256;mackpeart Dr 14v
39. Dsstox_cid_22254
40. Dsstox_rid_79975
41. Dsstox_gsid_42254
42. Mimyx
43. Palmidrolum [inn-latin]
44. Cas-544-31-0
45. Sr-01000076055
46. Einecs 208-867-9
47. Unii-6r8t1udm3v
48. N-(2-hydroxyethyl) Hexadecanamide
49. Hexadecanamide,n-(2-hydroxyethyl)-
50. Mackpeart Dr 14v
51. Mfcd00020562
52. Anandamide C16:0
53. 2-palmitoylaminoethanol
54. Palmdrol Prodes (tn)
55. Tocris-0879
56. N-palmitoyl Ethanolamide
57. N-hexadecyl-ethanolamine
58. Palmidrol [mi]
59. Lopac-p-0359
60. Palmidrol [mart.]
61. Palmitoylethanolamide-[d4]
62. Palmityoletanolamide (pea)
63. 2-palmitamidoethanol
64. Palmidrol [who-dd]
65. Cbiol_002043
66. Lopac0_000905
67. Bspbio_001454
68. Kbiogr_000174
69. Kbioss_000174
70. Mls002153421
71. Schembl120518
72. Palmitamide Mea [inci]
73. Bml2-b10
74. Chembl417675
75. Gtpl3622
76. Am-3112
77. Dtxsid4042254
78. Palmidrol
79. N-palmitoylethanolamine
80. Schembl19511663
81. Bdbm29083
82. Kbio2_000174
83. Kbio2_002742
84. Kbio2_005310
85. Kbio3_000347
86. Kbio3_000348
87. Bio1_000329
88. Bio1_000818
89. Bio1_001307
90. Bio2_000174
91. Bio2_000654
92. Hms1361i16
93. Hms1791i16
94. Hms1989i16
95. Hms2234l19
96. Hms3264c10
97. Hms3266n08
98. Hms3374k03
99. Hms3402i16
100. Hms3411b14
101. Hms3649l03
102. Hms3675b14
103. Pharmakon1600-01506156
104. Bcp29005
105. Cs-d1253
106. Nsc23320
107. Zinc8035017
108. Tox21_110222
109. Ana(16:0)
110. Lmfa08040013
111. Nae(16:0)
112. Nsc760371
113. S4708
114. Stl454872
115. Akos002676363
116. Tox21_110222_1
117. Ccg-204987
118. Db14043
119. Lp00905
120. Nsc-760371
121. Sdccgsbi-0050880.p002
122. Idi1_033924
123. S10398
124. Ncgc00015793-01
125. Ncgc00015793-02
126. Ncgc00015793-04
127. Ncgc00015793-05
128. Ncgc00015793-06
129. Ncgc00015793-07
130. Ncgc00015793-08
131. Ncgc00015793-09
132. Ncgc00015793-10
133. Ncgc00015793-12
134. Ncgc00024840-01
135. Ncgc00024840-02
136. Ncgc00024840-05
137. Ncgc00024840-06
138. Ncgc00024840-07
139. Ncgc00024840-08
140. Ncgc00024840-09
141. As-14094
142. Hy-20685
143. Palmitoylethanolamide [nflis-drug]
144. Smr000058371
145. Hexadecanoic Acid (2-hydroxy-ethyl)-amide
146. B6485
147. Eu-0100905
148. Ft-0778178
149. P2670
150. D08328
151. P 0359
152. Ab00918319_06
153. A904411
154. Q2159860
155. Sr-01000076055-1
156. Sr-01000076055-3
157. Sr-01000076055-7
158. Brd-k68095457-001-04-4
159. Z2687203832
| Molecular Weight | 299.5 g/mol |
|---|---|
| Molecular Formula | C18H37NO2 |
| XLogP3 | 6.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 16 |
| Exact Mass | 299.282429423 g/mol |
| Monoisotopic Mass | 299.282429423 g/mol |
| Topological Polar Surface Area | 49.3 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 219 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Cannabinoid Receptor Agonists
Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS. (See all compounds classified as Cannabinoid Receptor Agonists.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Equisetum Arvense is a Plant Extract/Herbal drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Chronic Pain.
Lead Product(s): Equisetum Arvense L.,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 07, 2025
Lead Product(s) : Equisetum Arvense L.,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Equisetum Arvense + PEA For Chronic Pain Management In Before-After Study
Details : Equisetum Arvense is a Plant Extract/Herbal drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Chronic Pain.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 07, 2025
Details:
Palmitoylethanolamide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Diabetic Neuropathies.
Lead Product(s): Palmitoylethanolamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Gencor Pacific Limited
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 19, 2025
Lead Product(s) : Palmitoylethanolamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Gencor Pacific Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy
Details : Palmitoylethanolamide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Diabetic Neuropathies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 19, 2025
Details:
Quantum BioPharma is advancing FSD202, an ultra-micronized PEA therapy, into a Phase 2 trial targeting chronic nociplastic pain in MCAS patients, addressing neuroimmune-driven pain.
Lead Product(s): Palmitoylethanolamide,Inapplicable
Therapeutic Area: Immunology Brand Name: FSD202
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Ingenu
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 04, 2025
Lead Product(s) : Palmitoylethanolamide,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Ingenu
Deal Size : Undisclosed
Deal Type : Partnership
iNGENu, Quantum BioPharma to Launch Australian Trial for Chronic Nociplastic Pain
Details : Quantum BioPharma is advancing FSD202, an ultra-micronized PEA therapy, into a Phase 2 trial targeting chronic nociplastic pain in MCAS patients, addressing neuroimmune-driven pain.
Product Name : FSD202
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 04, 2025
Details:
The SCI-210 therapy combines cannabidiol and SciSparc's Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.
Lead Product(s): Cannabidiol,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 31, 2024
Lead Product(s) : Cannabidiol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Announces Renewal Of Approval for Autism Spectrum Disorder Trial
Details : The SCI-210 therapy combines cannabidiol and SciSparc's Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 31, 2024
Details:
Palmitoylethanolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Lead Product(s): Palmitoylethanolamide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Gencor Pacific Limited
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 05, 2024
Lead Product(s) : Palmitoylethanolamide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Gencor Pacific Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Palmitoylethanolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 05, 2024
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Secures FDA Green Light for Phase IIb Clinical Trial in Tourette Syndrome
Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 30, 2024
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 23, 2024
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Receives FDA Approval for Phase IIb Trial in Tourette Syndrome
Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 23, 2024
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is being developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 18, 2024
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Submits IND for Phase IIb Trial for Tourette Syndrome Treatment
Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is being developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 18, 2024
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 23, 2024
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Submits IND for Phase IIb Trial of SCI-110 for Tourette Syndrome
Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 23, 2024
Details:
The SCI-210 therapy combines cannabidiol and SciSparc's Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.
Lead Product(s): Cannabidiol,Palmitoylethanolamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2024
Lead Product(s) : Cannabidiol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc Enrolls First Five Patients in Trial for SCI-210 Treatment
Details : The SCI-210 therapy combines cannabidiol and SciSparc's Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 19, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
13
PharmaCompass offers a list of Palmitoylethanolamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Palmitoylethanolamide manufacturer or Palmitoylethanolamide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Palmitoylethanolamide manufacturer or Palmitoylethanolamide supplier.
PharmaCompass also assists you with knowing the Palmitoylethanolamide API Price utilized in the formulation of products. Palmitoylethanolamide API Price is not always fixed or binding as the Palmitoylethanolamide Price is obtained through a variety of data sources. The Palmitoylethanolamide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Palmitoylethanolamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Palmitoylethanolamide, including repackagers and relabelers. The FDA regulates Palmitoylethanolamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Palmitoylethanolamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Palmitoylethanolamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Palmitoylethanolamide supplier is an individual or a company that provides Palmitoylethanolamide active pharmaceutical ingredient (API) or Palmitoylethanolamide finished formulations upon request. The Palmitoylethanolamide suppliers may include Palmitoylethanolamide API manufacturers, exporters, distributors and traders.
click here to find a list of Palmitoylethanolamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Palmitoylethanolamide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Palmitoylethanolamide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Palmitoylethanolamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Palmitoylethanolamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Palmitoylethanolamide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Palmitoylethanolamide suppliers with NDC on PharmaCompass.
Palmitoylethanolamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Palmitoylethanolamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Palmitoylethanolamide GMP manufacturer or Palmitoylethanolamide GMP API supplier for your needs.
A Palmitoylethanolamide CoA (Certificate of Analysis) is a formal document that attests to Palmitoylethanolamide's compliance with Palmitoylethanolamide specifications and serves as a tool for batch-level quality control.
Palmitoylethanolamide CoA mostly includes findings from lab analyses of a specific batch. For each Palmitoylethanolamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Palmitoylethanolamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Palmitoylethanolamide EP), Palmitoylethanolamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Palmitoylethanolamide USP).
